Intranasal Administration of PACAP Is an Efficient Delivery Route to Reduce Infarct Volume and Promote Functional Recovery After Transient and Permanent Middle Cerebral Artery Occlusion
Copyright policy )Intranasal Administration of PACAP Is an Efficient Delivery Route to Reduce Infarct Volume and Promote Functional Recovery After Transient and Permanent Middle Cerebral Artery Occlusion
Intranasal (IN) administration appears to be a suitable route for clinical use as it allows direct delivery of bioactive molecules to the central nervous system, reducing systemic exposure and sides effects. Nevertheless, only some molecules can be transported to the brain from the nasal cavity. This led us to compare the efficiency of an IN, intravenous (IV), and intraperitoneal (IP) administration of pituitary adenylate cyclase-activating polypeptide (PACAP) after transient or permanent middle cerebral artery occlusion (MCAO) in C57BL/6 mice. The results show that the neuroprotective effect of PACAP is much more efficient after IN administration than IV injection while IP injection had no effect. IN administration of PACAP reduced the infarct volume when injected within 6 h after the reperfusion and improved functional recovery up to at least 1 week after the ischemia.
- Inserm France
- Institut de Chimie France
- Normandie Université France
- University of Algiers 3 Algeria
- French Institute of Health and Medical Research France
Brain Infarction, Male, Middle Cerebral Artery, functional recovery, 610, MESH: Neurotransmitter Agents, Inbred C57BL, infarct volume, intranasal administration, cerebral ischemia, Diseases of the endocrine glands. Clinical endocrinology, MESH: Infarction, Mice, Endocrinology, MESH: Brain Infarction, [CHIM] Chemical Sciences, [CHIM]Chemical Sciences, Animals, MESH: Animals, MESH: Mice, Administration, Intranasal, Neurotransmitter Agents, MESH: Pituitary Adenylate Cyclase-Activating Polypeptide, Infarction, Middle Cerebral Artery, MESH: Neuroprotective Agents, Recovery of Function, MESH: Recovery of Function, RC648-665, MESH: Male, pituitary adenylate cyclase-activating polypeptide, Mice, Inbred C57BL, Neuroprotective Agents, Intranasal, Pituitary Adenylate Cyclase-Activating Polypeptide, MESH: Administration
Brain Infarction, Male, Middle Cerebral Artery, functional recovery, 610, MESH: Neurotransmitter Agents, Inbred C57BL, infarct volume, intranasal administration, cerebral ischemia, Diseases of the endocrine glands. Clinical endocrinology, MESH: Infarction, Mice, Endocrinology, MESH: Brain Infarction, [CHIM] Chemical Sciences, [CHIM]Chemical Sciences, Animals, MESH: Animals, MESH: Mice, Administration, Intranasal, Neurotransmitter Agents, MESH: Pituitary Adenylate Cyclase-Activating Polypeptide, Infarction, Middle Cerebral Artery, MESH: Neuroprotective Agents, Recovery of Function, MESH: Recovery of Function, RC648-665, MESH: Male, pituitary adenylate cyclase-activating polypeptide, Mice, Inbred C57BL, Neuroprotective Agents, Intranasal, Pituitary Adenylate Cyclase-Activating Polypeptide, MESH: Administration
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).22 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!